BioSante Pharmaceuticals, Inc. is a specialty pharmaceutical company established in 1996, focusing on pioneering advancements in female sexual health, menopause, contraception, and male hypogonadism. The company's flagship product, LibiGel, a once-daily transdermal testosterone gel, is currently in Phase III clinical development under a special protocol assessment (SPA) for treating female sexual dysfunction (FSD). Besides, BioSante offers Elestrin, a transdermal estradiol gel for treating vasomotor symptoms, The Pill-Plus for treating female sexual dysfunction in women using oral or transdermal contraceptives, and Bio-T-Gel for addressing hypogonadism in men, exemplifying the company's commitment to innovative treatment options.
The $18.00 million Post-IPO Equity investment received by BioSante Pharmaceuticals is a testament to investor confidence in the company's vision and products. The investment, led by Great Point Partners and Deerfield Capital Management, signifies the recognition of BioSante's potential in transforming the healthcare landscape and addressing unmet medical needs in its targeted therapeutic areas.
With a focus on crucial health sectors like biotechnology, healthcare, and pharmaceuticals, BioSante Pharmaceuticals stands poised to make a significant impact on the well-being of individuals around the world, offering innovative solutions to complex health issues. The company's dedication to pioneering advancements in critical health domains positions it as an attractive prospect for investors seeking opportunities in the pharmaceutical industry.
